OGNOrganon & Co.

$13.81+33% 1Y
Latest close: a new 52-week highOct 9, 2026what changed →

Is it growing?

Watch

Growth is fading: revenue shrinking (−2% year on year) and earnings down −71% year on year.

2 to watch, 1 without data
Revenue trend−2% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: −1% a year.

Earnings trend−71% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

All from SEC EDGAR, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearsbehind 79% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is OGN growing?

Organon & Co. has grown revenue −0.22% a year over three years and −0.64% a year over five, with earnings per share compounding at −36%.

−0.22%

Revenue growth, 3-year annual rate · Drug Manufacturers - General median +6.3% · shrinking · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate
−0.64%

Revenue growth, 5-year rate · −0.22% over three · growth has picked up over the last three years

Earnings per share, 3-year rate
−36%

Earnings per share, 3-year rate · revenue −0.22% · earnings lagged revenue: the growth is costing something

Years of annual history on file
7

Years of annual history on file · FY2019 to FY2025, as filed

Details›
Revenue FY2021
$6.30B
Revenue FY2022
$6.17B
Revenue FY2023
$6.26B
Revenue FY2024
$6.40B
Revenue FY2025
$6.22B

Annual income statements as filed with the SEC.